ESALF.US Eisai Co. Ltd

Healthcare Pharmaceuticals USA Stocks
32.58 USD
Close of Nov 14, 2026
23.49 33.12
Market cap
USD 9.18B
P/E
32.9x
P/B
1.63x
ROE
6.6%
Dividend yield
3.07%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.

Is ESALF.US undervalued?

Graham number
Price32.58
Graham value21.13
Premium54.2%

ESALF.US trades 54.2% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Eisai Co. Ltd fundamental analysis

No fundamental analysis for Eisai Co. Ltd yet.

Eisai Co. Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Eisai Co. Ltd

Eisai Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals in Japan. The company operates through pharmaceuticals business and other business segments. It offers Lenvima, a multi-kinase inhibitor which is involved in tumor angiogenesis or tumor malignancy; LEQEMBI, a humanized IgG1 monoclonal antibody against amyloid-beta (Aß) protofibrils; and Dayvigo, a novel small molecule compound. The company also provides prescription drugs; and over…

Full company profile